NovaVive Seeking to Enhance Quality of Life of Dogs with Cancer
Immunocidin is being evaluated in a clinical study as a palliative therapy for dogs with malignant cancer. The goal is to increase the dogs' comfort and maintain or improve the quality and duration of their remaining life.
Immunocidin® with Chemotherapy Extends Survival Time in Study with Canine Lymphoma and Osteosarcoma Patients
Positive data from a retrospective study using Immunocidin® with chemotherapy in dogs with Lymphoma and Osteosarcoma were presented at the Veterinary Cancer Society Annual Conference by Dr. Jeannette Kelly, vet oncologist.
ISU College of Veterinary Medicine to Conduct a Study with Immunocidin® in the Treatment of Canine Hemangiosarcoma
NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).
Immunocidin® Demonstrates an Acceptable Safety Profile Following Intravenous Administration in Dogs and Cats with Various Malignancies
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.
NovaVive Inc. Summarizes Canine Cancer Data Presented at World Veterinary Cancer Congress
The results of clinical studies using MCW formulations in ameliorating neutropenia and inducing serum cytokine synthesis were presented at the 3rd World Veterinary Cancer Congress (WVCC) in May, 2016 in Brazil.